Daniel Schneiderman - Mar 1, 2024 Form 4/A Insider Report for Pasithea Therapeutics Corp. (KTTA)

Role
Chief Financial Officer
Signature
/s/ Daniel Schneiderman
Stock symbol
KTTA
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4/A
Date filed
4/5/2024, 09:45 PM
Date Of Original Report
Mar 1, 2024
Previous filing
Oct 12, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTTA Stock Option (right to buy) Award $0 +10K $0.00 10K Mar 1, 2024 Common Stock 10K $8.13 Direct F1, F2
transaction KTTA Stock Option (right to buy) Award $0 +5.93K $0.00 5.93K Mar 1, 2024 Common Stock 5.93K $8.13 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
F2 The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date.
F3 The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024.

Remarks:

On January 2, 2024, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Common Stock, and the exercise price and shares of Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.